# Adversarial verification — osteoblastoma.md

1. DOSE LEAK: none. Grepped for numeric doses/mg/mg-m2/AUC/Gy/numbered schedules — the only
   digits in the file are "12th" (x2, in "DeVita ... 12th ed."). No drug doses, no fraction/Gy
   counts, no numbered regimen steps anywhere.

2. UNGROUNDED CLAIMS: none found beyond what the draft agent already disclosed. The file contains
   zero drug names, zero regimen/trial names, and zero statistics (no recurrence-rate percentages,
   no survival numbers). Every clinical assertion (curettage +/- bone grafting/cementation as
   first-line, en bloc resection for aggressive/recurrent lesions, no role for radiotherapy or
   systemic therapy in typical disease, spinal decompression/stabilization when neural structures
   are involved, referral to orthopedic oncology before biopsy given osteosarcoma overlap) is
   uncontroversial, guideline-standard management for a benign osteoblastic bone tumor and is
   explicitly and consistently labeled "general oncology standard, not from DeVita's section on
   this disease" rather than misattributed to DeVita. Verified against DeVita: grep confirms only
   two passing mentions of osteoblastoma exist in the text (line 220264, chondrosarcoma-etiology
   aside; line 221457, bone-mass differential-diagnosis list) — no dedicated management section —
   matching the draft agent's report exactly. No fabricated DeVita attribution detected.

3. CITATION: present. Line 5 states "DeVita, Hellman, and Rosenberg's Cancer: Principles &
   Practice of Oncology, 12th ed." (sourcing note, name only, no page numbers) and line 93 repeats
   it as the closing "Sources:" line. Also correctly caveated inline: the sourcing note and every
   management bullet honestly disclose that DeVita has no dedicated osteoblastoma management
   section and that the content is general-standard, not DeVita-derived, plus an explicit
   "FLAG: needs manual sourcing" banner.

4. VERDICT: CLEAN (ready for R1).
   Note for R1: this sidecar is unusually honest — it does NOT claim DeVita grounding for its
   management content (correctly, since DeVita has none for this benign tumor) and flags itself
   for manual sourcing against an orthopedic/WHO bone-tumor reference. R1 should treat the
   "FLAG: needs manual sourcing" as a real open item, not decoration - i.e. before this ships to
   the app, someone should confirm the surgical-management claims against a bone-tumor-specific
   source (WHO Classification of Tumours, Soft Tissue and Bone, or an orthopedic oncology text),
   since DeVita itself provides no support either way.
